Kessler, David

The author thanks Robert G. Kessler, David J. Sachi, Dee McKee, and the laboratory staff for their technical input and aid in these investigations. 

Gowrishankar Srmivasan, Michael Kessler David Grewell Department of Agricultural Biosystems Engineering Department of Material Science and Engineering Iowa State University, Iowa 50011, U.S.A... 

Pahents need informahon to use drugs properly, not only adequate direchons for use, but also informahon on the risks and benefits. Pharmacists are key players in the pahent educahon process. In an article in American Pharmacy in January of 1992, former FDA Commissioner, Dr. David Kessler challenged pharmacists to renew their commitment to... 

Kessler DA (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, Accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings before the Subcommittee on Health and... 

David Kessler, physician and commissioner of the Food and Drug Administration from 1990 to 1997. While commissioner, he opposed DTC advertising and issued draft regulations for these ads. Later, when serving as dean of Yale Medical School, he came to support advertising of prescription drugs as a way to get information to the public. 

Many women who have received silicone-fluid-filled breast implants have claimed to suffer from implant-related diseases, apparently caused by small leakages of the fluid into the body tissue. Successful lawsuits on those grounds in the United States have driven Dow Corning, the principal manufacturer of the implants, to file for bankruptcy protection. Food and Drug Administration Commissioner David A. Kessler, however, has reported to a congressional subcommittee that, as of July, 1995, there was no scientific evidence that silicone implants are a significant cause of disease. See M. S. Reisch and R. L. Rawls, Silicone gel breast implants. Chem. Eng. News, December 11, 10-17 (1995). 

When he became FDA commissioner in 1991, David Kessler promised dramatic changes, that—to use a term he repeated in many lectures—he would teach the elephant to dance. And Kessler did—to a tune called by flacks and politicians. Right out... 

Fifty additional reviewers (for a total of 250) and the appointment of Kathryn C. Zoon, as a new director tor the Cenier for Biologies Evaluation and Research, occurred in 1992, under the leadership of FDA commissioner David Kessler, despite the lack of additional funding for the FDA to carry this out (Ember). By 1996, 500 new scientific staff (from microbiologists to statisticians) had been hired to review applications. The funds for the additional staffing resulted from authorization by Congress for the FDA to collect user fees from the industry. 

Writing in the Journal of the American Medical Association on behalf of the FDA, former Commissioner David Kessler (1993) declared ... 

Public Citizen s Health Research Group. (1991, May 23). Re Citizen s petition for revision of fluoxetine (Prozac) labeling Letter to David Kessler, Commissioner, Food and Drug Administration. Washington, DC Author. 

According to the FDA Commissioner at the time, David Kessler, the increased money resulted in faster drug application reviews. The General Accounting Office (GAO) reported that the average approval times for new drug applications (NDAs) submitted to the FDA in 1987 and 1992 were 33 and 19 months, respectively. As Dr. Kessler states ... 

A draft of this chapter benefited from comments by Patrick Crill, Jennifer King, John Kessler, Stan Tyler, David Valentine, Steve Whalen, and an anonymous reviewer. Don Blake, Tom Graedel, M. A. K. Khalil, and F. S. Rowland provided perspective on obervations documenting the atmospheric methane increase. This work was supported by the National Science Foundation. I thank all of the above for their help. 

David P. Kessler / Department of Chemical Engineering, Purdue University,... 

Initially the MEDWatch program was intended to simplify reporting and enroll more physicians and other health professionals in the process of reporting side effects. According to FDA Commissioner David Kessler, "It is not in... 

Kessler et al. (1984) developed a glucose sensor with an extremely low oxygen demand and a stability of 3 months, which appears to be suitable for implantation. Another sensor that might be implantable is based on the use of ferrocene as an electron acceptor for GOD (Cass et al., 1984 David et al., 1985), which eliminates the need for oxygen. The sensor exhibits an advantageous linear range of 1-30 mmol/l. However, experiments with the sensor implanted subcutaneously in animals revealed a rapid sensitivity decrease (Pickup, 1987). 

David A. Kessler, Charles P. Marsh and Sean Morefield... 

---